Cargando…
Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis
In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry c...
Autores principales: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096452/ https://www.ncbi.nlm.nih.gov/pubmed/32214132 http://dx.doi.org/10.1038/s41598-020-61991-3 |
_version_ | 1783510806937206784 |
---|---|
author | Hsu, Wei-Fan Chen, Chi-Yi Tseng, Kuo-Chih Lai, Hsueh-Chou Kuo, Hsing-Tao Hung, Chao-Hung Tung, Shui-Yi Wang, Jing-Houng Chen, Jyh-Jou Lee, Pei-Lun Chien, Rong-Nan Lin, Chun-Yen Yang, Chi-Chieh Lo, Gin-Ho Tai, Chi-Ming Lin, Chih-Wen Kao, Jia-Horng Liu, Chun-Jen Liu, Chen-Hua Yan, Sheng-Lei Bair, Ming-Jong Su, Wei-Wen Chu, Cheng-Hsin Chen, Chih-Jen Lo, Ching-Chu Cheng, Pin-Nan Chiu, Yen-Cheng Wang, Chia-Chi Cheng, Jin-Shiung Tsai, Wei-Lun Lin, Han-Chieh Huang, Yi-Hsiang Tsai, Pei-Chien Huang, Jee-Fu Dai, Chia-Yen Chuang, Wan-Long Yu, Ming-Lung Peng, Cheng-Yuan |
author_facet | Hsu, Wei-Fan Chen, Chi-Yi Tseng, Kuo-Chih Lai, Hsueh-Chou Kuo, Hsing-Tao Hung, Chao-Hung Tung, Shui-Yi Wang, Jing-Houng Chen, Jyh-Jou Lee, Pei-Lun Chien, Rong-Nan Lin, Chun-Yen Yang, Chi-Chieh Lo, Gin-Ho Tai, Chi-Ming Lin, Chih-Wen Kao, Jia-Horng Liu, Chun-Jen Liu, Chen-Hua Yan, Sheng-Lei Bair, Ming-Jong Su, Wei-Wen Chu, Cheng-Hsin Chen, Chih-Jen Lo, Ching-Chu Cheng, Pin-Nan Chiu, Yen-Cheng Wang, Chia-Chi Cheng, Jin-Shiung Tsai, Wei-Lun Lin, Han-Chieh Huang, Yi-Hsiang Tsai, Pei-Chien Huang, Jee-Fu Dai, Chia-Yen Chuang, Wan-Long Yu, Ming-Lung Peng, Cheng-Yuan |
author_sort | Hsu, Wei-Fan |
collection | PubMed |
description | In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m(2) was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients. |
format | Online Article Text |
id | pubmed-7096452 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | Nature Publishing Group UK |
record_format | MEDLINE/PubMed |
spelling | pubmed-70964522020-03-30 Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis Hsu, Wei-Fan Chen, Chi-Yi Tseng, Kuo-Chih Lai, Hsueh-Chou Kuo, Hsing-Tao Hung, Chao-Hung Tung, Shui-Yi Wang, Jing-Houng Chen, Jyh-Jou Lee, Pei-Lun Chien, Rong-Nan Lin, Chun-Yen Yang, Chi-Chieh Lo, Gin-Ho Tai, Chi-Ming Lin, Chih-Wen Kao, Jia-Horng Liu, Chun-Jen Liu, Chen-Hua Yan, Sheng-Lei Bair, Ming-Jong Su, Wei-Wen Chu, Cheng-Hsin Chen, Chih-Jen Lo, Ching-Chu Cheng, Pin-Nan Chiu, Yen-Cheng Wang, Chia-Chi Cheng, Jin-Shiung Tsai, Wei-Lun Lin, Han-Chieh Huang, Yi-Hsiang Tsai, Pei-Chien Huang, Jee-Fu Dai, Chia-Yen Chuang, Wan-Long Yu, Ming-Lung Peng, Cheng-Yuan Sci Rep Article In patients with chronic hepatitis C (CHC), the effects of baseline characteristics, virological profiles, and therapeutic outcome to pegylated interferon plus ribavirin (PR) therapy on autoimmune diseases are unknown. Taiwanese Chronic Hepatitis C Cohort is a nationwide hepatitis C virus registry cohort comprising 23 hospitals of Taiwan. A total of 12,770 CHC patients receiving PR therapy for at least 4 weeks between January 2003 and December 2015 were enrolled and their data were linked to the Taiwan National Health Insurance Research Database for studying the development of 10 autoimmune diseases. The mean follow-up duration was 5.3 ± 2.9 years with a total of 67,930 person-years, and the annual incidence of systemic lupus erythematosus (SLE) or rheumatoid arthritis (RA) was 0.03%. Other autoimmune diseases were not assessable due to few events. Body mass index ≥24 kg/m(2) was an independent predictor of the low incidence of SLE or RA (hazard ratio 0.40, 95% confidence interval 0.17–0.93, p = 0.034). A sustained virological response (SVR) to PR therapy was not associated with the low incidence of SLE or RA in any subgroup analysis. CHC patients achieving SVR to PR therapy did not exhibit an impact on the incidence of SLE or RA compared with non-SVR patients. Nature Publishing Group UK 2020-03-25 /pmc/articles/PMC7096452/ /pubmed/32214132 http://dx.doi.org/10.1038/s41598-020-61991-3 Text en © The Author(s) 2020 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/. |
spellingShingle | Article Hsu, Wei-Fan Chen, Chi-Yi Tseng, Kuo-Chih Lai, Hsueh-Chou Kuo, Hsing-Tao Hung, Chao-Hung Tung, Shui-Yi Wang, Jing-Houng Chen, Jyh-Jou Lee, Pei-Lun Chien, Rong-Nan Lin, Chun-Yen Yang, Chi-Chieh Lo, Gin-Ho Tai, Chi-Ming Lin, Chih-Wen Kao, Jia-Horng Liu, Chun-Jen Liu, Chen-Hua Yan, Sheng-Lei Bair, Ming-Jong Su, Wei-Wen Chu, Cheng-Hsin Chen, Chih-Jen Lo, Ching-Chu Cheng, Pin-Nan Chiu, Yen-Cheng Wang, Chia-Chi Cheng, Jin-Shiung Tsai, Wei-Lun Lin, Han-Chieh Huang, Yi-Hsiang Tsai, Pei-Chien Huang, Jee-Fu Dai, Chia-Yen Chuang, Wan-Long Yu, Ming-Lung Peng, Cheng-Yuan Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
title | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
title_full | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
title_fullStr | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
title_full_unstemmed | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
title_short | Sustained virological response to hepatitis C therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
title_sort | sustained virological response to hepatitis c therapy does not decrease the incidence of systemic lupus erythematosus or rheumatoid arthritis |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7096452/ https://www.ncbi.nlm.nih.gov/pubmed/32214132 http://dx.doi.org/10.1038/s41598-020-61991-3 |
work_keys_str_mv | AT hsuweifan sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chenchiyi sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT tsengkuochih sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT laihsuehchou sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT kuohsingtao sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT hungchaohung sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT tungshuiyi sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT wangjinghoung sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chenjyhjou sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT leepeilun sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chienrongnan sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT linchunyen sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT yangchichieh sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT loginho sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT taichiming sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT linchihwen sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT kaojiahorng sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT liuchunjen sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT liuchenhua sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT yanshenglei sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT bairmingjong sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT suweiwen sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chuchenghsin sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chenchihjen sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT lochingchu sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chengpinnan sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chiuyencheng sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT wangchiachi sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chengjinshiung sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT tsaiweilun sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT linhanchieh sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT huangyihsiang sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT tsaipeichien sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT huangjeefu sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT daichiayen sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT chuangwanlong sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT yuminglung sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis AT pengchengyuan sustainedvirologicalresponsetohepatitisctherapydoesnotdecreasetheincidenceofsystemiclupuserythematosusorrheumatoidarthritis |